Seladelpar for bile duct narrowing after liver transplant
Part of Digestive system clinical trials.
This study tests a medication called seladelpar to see if it can help treat narrowed bile ducts (ischemic cholangiopathy) that can occur after a liver transplant. It may be an option for people who are otherwise stable and not dealing with other major health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You have a liver transplant and were diagnosed with ischemic cholangiopathy (narrowed bile ducts) within the last year (but not sooner than 4 weeks after transplant).
- Your blood tests show high alkaline phosphatase and GGT levels, indicating possible bile flow problems.
- You have not been hospitalized in the last 2 weeks and are not currently very sick from other conditions.
- You are not pregnant, breastfeeding, or taking certain other medications (like cyclosporine or fenofibrate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an endoscopic (camera-based) approach to treat bile duct narrowing that happens after a liver transplant. It may help improve bile flow and liver blood test results when the narrowing is in the bile duct area near where the liver’s bile ducts split.
This study is testing a special temporary stent that breaks down over time to help open a narrowed bile duct after a liver transplant. It may help avoid long-term plastic stents or additional surgery.
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
This study tests whether stem cells from donated fat tissue can help prevent bile duct problems after a living-donor liver transplant. It is for adult patients who are listed for a transplant and will receive a liver from a living donor.
This study tests an experimental oral drug called seladelpar for people with PBC who also have cirrhosis that is well-controlled. The goal is to see if it helps improve liver health and manage symptoms without causing serious side effects.
This study follows patients who are already taking seladelpar (a medication) for primary biliary cirrhosis—a liver disease where the immune system damages bile ducts. Researchers want to understand how well the medication works and how safe it is when used in everyday clinical practice outside of controlled trials.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.